Working... Menu

Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03643887
Recruitment Status : Not yet recruiting
First Posted : August 23, 2018
Last Update Posted : August 23, 2018
Information provided by (Responsible Party):
University of Wisconsin, Madison

Tracking Information
First Submitted Date  ICMJE August 21, 2018
First Posted Date  ICMJE August 23, 2018
Last Update Posted Date August 23, 2018
Estimated Study Start Date  ICMJE July 1, 2019
Estimated Primary Completion Date June 1, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 22, 2018)
Compare incidence of VRE/CRE decolonization between FMT Capsule double encapsuled (DE) and placebo [ Time Frame: 6 months ]
VRE/CRE decolonization is defined by absence of VRE/CRE on stool culture using standard laboratory techniques.
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: August 22, 2018)
  • VRE/CRE infection at Day 3, Day 10, and Week 4 following randomization. [ Time Frame: 1 month ]
    VRE/CRE infection will be defined as an associated bacteremia, urinary tract infection, or would-related infection.
  • Microbial engraftment assessed by microbial disruption index (MDI) at Day 3, Day 10, and Week 4 following randomization [ Time Frame: 1 month ]
    VRE/CRE type and strain level engraftment, using whole genome sequencing laboratory techniques
  • Antibiotic resistant bacteria (ARB) decolonization at Day 10 after randomization. [ Time Frame: 10 days ]
    ARB testing will be done with Acuitas (OpGen) MDRO test or a similar platform
  • Antibiotic resistant bacteria (ARB) infection at Day 3, Day 10, Week 4 after randomization, and time to infection if ARB infection occurs [ Time Frame: 1 month ]
    ARB infection will be defined as extended spectrum beta lactamase clinical infection.
  • Adverse events/serious adverse events through Day 10, Week 4, and Month 6 following randomization. [ Time Frame: 6 months ]
    Safety of FMT Capsule DE compared to placebo. Incidence of newly acquired transmissible infectious diseases that are considered adverse events of special interest (AESI).
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients
Official Title  ICMJE A Phase II Randomized, Double-blind Placebo-controlled Trial of Fecal Microbiota Transplantation for Vancomycin-resistant Enterococcus and Carbapenem-resistant Enterobacteriaceae
Brief Summary Vancomycin-resistant Enterococcus (VRE) and carbapenem-resistant Enterobacteriaceae (CRE) are multi-drug resistant organisms (MDROs) associated with healthcare settings and are a high priority for containment in public health. Healthcare-associated infections (HAIs) like VRE and CRE lengthen the duration of a hospital stay, increase the cost of hospitalization, and increase mortality. Because colonization precedes infection, prevention or treatment of VRE/CRE colonization is essential. We propose a treatment approach to promote gut decolonization by VRE and CRE without using antibiotics. Participants enrolled in this study will be randomized a one-time dose of either study drug or placebo, will be followed for 6 months, and will submit stool samples for analysis of several outcomes for the trial.
Detailed Description This is a phase II, double-blind, randomized, placebo controlled trial assessing the effects of one-time oral FMT on the composition and function of the gut microbiome compared to placebo in a population of patients with baseline CRE or VRE gut colonization. Participants will be adults who have had two consecutive positive stool cultures for VRE or CRE and meet all inclusion/exclusion criteria. Patients (N=90) will be randomized at a 1:1 ratio. Randomization will be double-blinded. Each subject will be followed for 6 months. Stool samples will be taken at baseline and from subjects weekly for 4 weeks, then every 4 weeks for 8 weeks, then at 6 months regardless of treatment group. All patients will be asked to complete a stool diary
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Double-blind, randomized, placebo controlled trial
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Condition  ICMJE Clostridium Difficile Infection
Intervention  ICMJE
  • Drug: FMT Capsule DE
    30 capsule one-time oral dose
  • Drug: Placebo oral capsule
    30 capsule one-time oral dose
    Other Name: Placebo
Study Arms  ICMJE
  • Experimental: FMT Capsule DE
    FMT Capsule DE
    Intervention: Drug: FMT Capsule DE
  • Placebo Comparator: Placebo Oral Capsule
    Placebo Capsule
    Intervention: Drug: Placebo oral capsule
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: August 22, 2018)
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 30, 2022
Estimated Primary Completion Date June 1, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Cognitively intact and willing to provide informed consent
  • Willing and able to comply with all study procedures for the duration of the study
  • Age 18 years or older
  • Two positive stool cultures for CRE or VRE (positive for the same organism on both cultures). The most recent stool culture must be within 14 days of randomization.
  • Women of childbearing potential in a sexual relationship with men must use an acceptable method of contraception (including, but not limited to, barrier with additional spermicidal foam or jelly, intrauterine device, hormonal contraception started at least 30 days before enrollment into the study, or intercourse with men who underwent a vasectomy) for 4 weeks following completion of the study treatment.
  • Males must agree to avoid impregnation of women during and for 4 weeks following completion of the study treatment through the use of an acceptable method of contraception (including but not limited to, barrier with additional spermicidal foam or jelly or vasectomy).
  • Able to take the test capsule successfully with no signs or symptoms of dysphagia.

Exclusion Criteria:

  • Admitted to an intensive care unit (ICU) for medical reasons (not just boarding).

Patients residing in a nursing home, long-term care facility or rehabilitation center may be enrolled.

  • Patient received antibiotics in the last 48 hours. Patients will be eligible to enroll if antibiotic therapy is discontinued for at minimum 48 hours prior to randomization. Does not include antibiotics used for prophylaxis or topical antibiotics.
  • Requires continued antibiotic use or anticipates antibiotic use in the upcoming 4 weeks.
  • Unwilling to withhold probiotics for a minimum of 48 hours prior to providing a screening stool sample.
  • Previous FMT or microbiome-based products in the last 90 days.
  • Active antibiotic-resistant bacteria (ARB) or gastrointestinal infection at time of enrollment.
  • Any other gastrointestinal illness including diarrhea.
  • Known or suspected toxic megacolon and or known small bowel ileus.
  • Bowel obstruction or other gut motility issues as noted by the patient or in the electronic medical record.
  • Major gastrointestinal surgery (e.g. significant bowel resection) within 3 months before enrollment not including appendectomy or cholecystectomy.
  • History of total colectomy or bariatric surgery.
  • Concurrent intensive induction chemotherapy, radiation therapy, or biologic treatment for an active malignancy. Patients on maintenance chemotherapy may be enrolled after consultation with the medical monitor.
  • Patients with severe anaphylactic or anaphylactoid food allergy.
  • Solid organ transplant recipients ≤90 days post-transplant or on active treatment for rejection.
  • Neutropenia (≤500 neutrophils/mL) or other severe immunosuppression. Anti-tumor necrosis factor (anti-TNF) will be permitted. Participants taking glucocorticoids, antimetabolites (azathioprine, 6-mercaptopurine, methotrexate), calcineurin inhibitors (tacrolimus, cyclosporine) and mycophenolate mofetil may be enrolled only after consultation with the medical monitor.
  • If At risk of CMV/EBV associated disease (at discretion of investigators, e.g. immunocompromised participant), negative Immunoglobulin G (IgG) testing for cytomegalovirus (CMV) or Epstein Barr Virus (EBV).
  • Cognitive impairment at the time of enrollment.
  • Expected life expectancy <6 months.
  • Inability (e.g. dysphagia) to or unwilling to swallow capsules.
  • Unable or unwilling to comply with protocol requirements.
  • Any condition that would jeopardize the safety or rights of the patient, would make it unlikely for the patient to complete the study, or would confound the results of the study.
  • Females who are pregnant, lactating, or planning to become pregnant during the study.

Female patients of childbearing potential will take a pregnancy test and be excluded if pregnant.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Michele L Zimbric, BS 608-265-8799
Contact: Ashley M Kates, PhD 608-256-1901
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT03643887
Other Study ID Numbers  ICMJE W81XWH18PRMPCTA
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Plan Description: Undecided until funded.
Responsible Party University of Wisconsin, Madison
Study Sponsor  ICMJE University of Wisconsin, Madison
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Nasia Safdar, MD PhD Infectious Disease, School of Medicine & Public Health, University of Wisconsin-Madison
PRS Account University of Wisconsin, Madison
Verification Date August 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP